News | Heart Failure | October 12, 2022

Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines 

The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines

October 12, 2022 —   Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month, Philips announced the results of an expert panel study [1] demonstrating the clinical and operational benefits of the company’s cardiovascular ultrasound and informatics portfolio to support diagnostic confidence, clinical efficiency and improve patient and staff experiences. The study was conducted using the Delphi method [2] which is widely used in capturing expert opinions and establishing professional and clinical guidance and consensus for decisions on the diagnosis and treatment of patients.

While using the Philips integrated Philips cardiovascular ultrasound analysis and reporting system, 86% of the study respondents agreed it can help increase confidence in diagnosis decision-making and improve the staff experience by providing access to the necessary patient data [3]. Respondents (100%) also agreed the Philips echocardiography solution has led to increased report and measurement consistency and/or reproducibility, improved time to detection and diagnosis, and could benefit their overall clinical daily work [3].

Decision-making has been enhanced using Philips’ integrated echocardiography solution in any scenario that needs several measurements, and/or requires consistency and comparison with previous measurements. Examples include valvular heart disease, adult congenital disease, and cancer patients [4]. Philips’ integrated echocardiography solution also enhances clinicians’ ability to follow the recently released European Society of Cardiology (ESC) Cardiology-oncology Guidelines (ESC Guidelines - Cancer treatments & cardiovascular toxicity (2016 ESC Position Paper) (escardio.org)), highlighting the prominence of echocardiography and access to consistent and reproducible measurements demonstrating great benefit with cardio-oncology assessments.

Significant challenges in echocardiography – improving efficiency of echo labs and cardiovascular service lines; shortening report turnaround times; reducing the need for repeat exams; enabling cross organizational collaboration; and ensuring high confidence diagnoses for complex cases – are often exacerbated by poor access to historical imaging and non-imaging data for individual patients. By integrating its cardiac ultrasound systems (EPIQ CVx and Affiniti) with its Ultrasound Workspace visualization/analysis workstation and its image and information management solution, IntelliSpace Cardiovascular, Philips’ solution for echocardiology helps address these challenges. 

By combining high image quality with AI and advanced analysis tools accessible both on and off-cart, Philips’ integrated echocardiography solution enables flexible clinical workflows and easy access to web-based chronological patient data to support collaboration and drive confident decision-making, all while reducing report turnaround time and time to diagnosis. As a full, vendor neutral solution, it enables integration with existing ultrasound systems and hospital IT infrastructure, helping to scale and realize the value of echocardiography to expanded applications, such as the cardio-oncology.

The combination of components of Philips’ echocardiography solution to help drive clinical, operational and workflow benefits include: 

  • Philips’ ultrasound system EPIQ CVx delivers exceptional 2D and 3D image quality and data precision needed to achieve high-confidence diagnoses to help improve patient outcomes. 
  • Philips multi-modality image and information management system – IntelliSpace Cardiovascular – helps streamline workflow and improve operational performance throughout the cardiovascular care pathway by bringing the echocardiography insights into context with the other imaging and information with a patient time line. 
  • Ultrasound Workspace, a scalable, vendor-neutral cardiovascular viewing, analysis and reporting system for both private practice and small labs, easily integrates into both Philips and non-Philips PACS and EMR environments for clinicians to leverage seamless diagnostic workflows from the ultrasound exam room to the reporting room and beyond, wherever echocardiography data needs to be reviewed and analyzed. 

Also during the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain, Philips organized an expert speaker symposium to discuss the latest advances in echocardiography. To further promote the results of the Delphi study, Philips has also published a new position paper titled ‘Helping to advance and shape the future of echocardiology’, based on an extensive customer survey aimed at identifying the potential for integrated echocardiography solutions to bring about transformative change in diagnosis, workflows, and operations.

For more information: https://www.usa.philips.com/healthcare/medical-specialties/cardiology

References:

[1] S. Boonyaratavej, F. Riccobene, F. Falahi, J. Franke, J. Solis, R. M. Lang. Assessment of benefits of Echo Workflow Solution: Findings from a two-step Delphi study, medRxiv 2022.06.01.22275807; doi: https://doi.org/10.1101/2022.06.01.22275807
[2] “Delphi” is a qualitative study methodology. The Delphi method requires subject matter experts to answer several rounds of in-depth interview questions to “forecast” future developments in their area of expertise.
Delphi Method | University of Phoenix Research Hub.
[3] Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[4[ Assessment of benefits of Echo Workflow Solution: Findings from a two-step Delphi study : S. Boonyaratavej, F. Riccobene, F. Falahi, J. Franke, J. Solis, R. M. Lang, medRxiv 2022.06.01.22275807; doi: https://doi.org/10.1101/2022.06.01.22275807 

 

Find more content from ESC22


Related Content

News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
News | Ventricular Assist Devices (VAD)

April 28, 2022 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers to the possibility that ...

Home April 28, 2022
Home
Subscribe Now